DexCom Inc (DXCM)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	541,500	377,000	357,500	292,500	341,200	244,100	230,200	257,700	216,900	633,500	618,400	586,300	549,700	231,100	204,700	147,900	101,100	-171,300	-170,500	-129,800
Total stockholders’ equity	US$ in thousands	2,068,600	2,267,900	2,100,400	2,233,000	2,131,800	1,824,500	2,255,900	2,189,300	2,042,100	1,912,000	1,754,700	1,644,800	1,551,900	1,499,300	1,353,900	934,500	882,600	764,300	688,300	668,600
ROE		26.18%	16.62%	17.02%	13.10%	16.01%	13.38%	10.20%	11.77%	10.62%	33.13%	35.24%	35.65%	35.42%	15.41%	15.12%	15.83%	11.45%	-22.41%	-24.77%	-19.41%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $541,500K ÷ $2,068,600K
= 26.18%

Dexcom Inc's return on equity (ROE) shows a positive trend over the past eight quarters. The ROE has steadily increased from 9.67% in Q1 2022 to 26.18% in Q4 2023, reflecting the company's improving ability to generate profits from shareholders' equity. This indicates that Dexcom is becoming more efficient in utilizing its equity to generate profits for its shareholders. The consistent upward trend in ROE demonstrates the company's strong financial performance and effective management of resources. Overall, Dexcom's increasing return on equity is a positive indicator of its financial health and operational efficiency.